Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

NCT04676867 is registered in ClinicalTrials.gov with DalCor Pharmaceuticals as lead sponsor.

NCT NCT04676867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
Lead sponsor
DalCor Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2021
Completion date
May 17, 2021
Enrollment
227 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19